DAIICHI SANKYO COMPANY,LIMITED [4568.T]
TOKYO, Apr 15 (Pulse News Wire) – Daiichi Sankyo Company,limited (4568.T) agreed to transfer all shares of its subsidiary Daiichi Sankyo Healthcare (DSHC) to Suntory Holdings Limited in a staged process. The agreement was formalized , with the initial phase set for June 1, 2026, and completion expected by June 1, 2027.
The total value of the share transfer is estimated at ¥246.5 billion. DSHC, known for OTC medications and expanding into functional skincare, oral care, and food products, will benefit from Suntory's strong foundation in beverages and health foods. Daiichi Sankyo plans to focus its resources on innovative medicines in areas such as cancer treatment. The transfer will reduce Daiichi Sankyo’s holding ratio in DSHC to 70% by March 31, 2026, and fully complete by June 1, 2029.
Financial highlights show DSHC had revenues of ¥60.12 billion in fiscal 2023, increasing to ¥76.05 billion in fiscal 2025. Operating profit rose from ¥10.95 billion in 2023 to ¥12.92 billion in 2025. The company paid dividends of ¥2.00 trillion per share in fiscal 2023, rising to ¥3.06 trillion per share in fiscal 2025. The impact on Daiichi Sankyo’s consolidated performance for the fiscal year ending March 2027 is currently being assessed, with anticipated revenue recognition in fiscal 2028.
🟡 Confidence: Standard AI-translated content.